Randox joins Action Cancer in the fight against Colorectal Cancer
Randox has launched a partnership with Northern Ireland's leading local cancer charity, Action Cancer, to raise public awareness of the symptoms of colorectal cancer (also called bowel cancer).
Colorectal cancer is the third most common type of cancer, however it is also one of the most curable if treated at an early stage. Screening can detect colorectal cancer before symptoms occur.
Randox is a privately owned diagnostic reagent and equipment manufacturer. Founded in 1982 by Dr Peter FitzGerald, Randox is a multimillion pound business employing over 600 people, including 185 research scientists. Since its inception in 1982, Randox have developed some of the most exciting and revolutionary technology in the field of medical diagnostics.
Randox have sales and distribution agreements in 130 countries and international offices with representation in the continents of Africa, Asia, Australia, Europe, North America and South America. Our core products and services are Biochip Array Technology, clinical chemistry automation systems, external quality assurance schemes, Internet driven QA systems, quality control materials, antibodies, recombinant proteins, clinical reagents and environmental diagnostics.
Related Links
To browse within the Randox website click on one of the links in the top or right hand navigation bars. To see links to information websites, select from the following list.
Randox Customer Service MAY6
Randox Laboratories Ltd. has built a reputation for customer support services of the highest standard.
May 6, 2008
Testing for renal function
Randox Laboratories Ltd. have developed four tests for the assessment of renal function.
May 1, 2008
High sensitivity cytokine assays
Cytokines and growth factors circulate in low quantities, thus high sensitivity detection is essential.
April 28, 2008
